Neuropeptides

Neuropeptides are short-chain amino acid sequences (typically 3–100 residues) that function as signaling molecules in the nervous system. They are synthesized by neurons, stored in dense-core vesicles, and released to modulate neural circuit activity — influencing pain perception, mood, appetite, stress responses, sleep, social behavior, and neuroendocrine function.

There are over 100 identified neuropeptides in the human nervous system. They represent one of the oldest and most diverse signaling systems in biology, predating classical neurotransmitters by hundreds of millions of years of evolution.

Neuropeptides vs. neurotransmitters

The distinction matters for understanding how peptide therapies work:

| Property | Neurotransmitters | Neuropeptides |

|---|---|---|

| Size | Small molecules (dopamine, serotonin, GABA) | 3–100 amino acids |

| Synthesis | Enzymatic, in nerve terminal | Ribosomal, in cell body (gene-encoded) |

| Storage | Small synaptic vesicles | Large dense-core vesicles |

| Release | Fast (milliseconds), at synaptic cleft | Slow (seconds), often extrasynaptic |

| Action | Fast, point-to-point | Slow, diffuse (volume transmission) |

| Receptors | Ion channels or GPCRs | Almost exclusively GPCRs |

| Reuptake | Yes (transporters recycle them) | No (degraded by peptidases) |

The key concept is volume transmission: neuropeptides are released not just at synapses but into the extracellular space, diffusing to affect distant neurons and glial cells. This makes them modulators of neural circuit tone rather than point-to-point signal carriers. A neuropeptide doesn't fire a single neuron — it adjusts the gain of entire neural networks.

Major neuropeptide families

Opioid peptides (endorphins, enkephalins, dynorphins)

The endogenous pain-modulation system. Beta-endorphin binds mu-opioid receptors — the same receptors targeted by morphine. Enkephalins modulate pain at the spinal level. Dynorphins activate kappa-opioid receptors, influencing dysphoria and stress responses.

These peptides are released during exercise (the "runner's high"), social bonding, and acute stress. Their therapeutic relevance: understanding endogenous opioid peptides has informed pain management, addiction research, and the development of opioid-sparing analgesics.

Oxytocin and vasopressin

Nine-amino-acid peptides produced in the hypothalamus with profound effects on social behavior, bonding, trust, and stress responses. Oxytocin is one of the most-studied neuropeptides — intranasal oxytocin research has explored applications in autism spectrum disorder, social anxiety, and PTSD, with mixed but interesting results.

Vasopressin (ADH) regulates water balance peripherally but centrally modulates aggression, pair bonding, and territorial behavior. The oxytocin/vasopressin balance is central to social neuroscience.

Vasoactive Intestinal Peptide (VIP)

A 28-amino acid neuropeptide with dual roles: peripherally it regulates GI motility, blood flow, and immune function; centrally it modulates circadian rhythms (VIP is a key clock signal in the suprachiasmatic nucleus), neuroprotection, and learning. VIP deficiency has been linked to CIRS (Chronic Inflammatory Response Syndrome) in the integrative medicine literature.

Orexins (hypocretins)

Hypothalamic neuropeptides that regulate wakefulness, appetite, and reward. Loss of orexin-producing neurons causes narcolepsy — one of the clearest neuropeptide-disease links in medicine. Dual orexin receptor antagonists (suvorexant, lemborexant) are now approved insomnia treatments, making orexins one of the most clinically validated neuropeptide targets.

Substance P and neurokinins

Substance P is an 11-amino acid neuropeptide central to pain transmission and neurogenic inflammation. It activates NK1 receptors in the dorsal horn of the spinal cord, amplifying pain signals. NK1 receptor antagonists (aprepitant) are used clinically as anti-emetics and are being explored for depression and pain.

DSIP (Delta-Sleep-Inducing Peptide)

A nonapeptide isolated from sleeping rabbit brains that modulates sleep architecture — increasing slow-wave (delta) sleep without sedation or REM suppression. DSIP is one of the few neuropeptides directly sold in the research peptide market for its sleep-modulating potential.

Why neuropeptides are difficult drug targets

Despite their biological importance, neuropeptides present significant pharmacological challenges:

Delivery: most neuropeptides cannot cross the blood-brain barrier when administered peripherally. Intranasal delivery (used for oxytocin, Semax, Selank) provides partial CNS access via the olfactory nerve pathway, but bioavailability is variable.

Stability: neuropeptides are rapidly degraded by peptidases (aminopeptidases, endopeptidases, angiotensin-converting enzyme). Plasma half-lives are often minutes. This has driven the development of stabilized analogs (Semax adds a Pro-Gly-Pro tail to ACTH4-7 for protease resistance).

Receptor complexity: neuropeptide receptors are almost exclusively G-protein coupled receptors (GPCRs), which signal through complex intracellular cascades with context-dependent effects. The same receptor can produce different downstream responses depending on the cell type, receptor density, and signaling partners.

Therapeutic neuropeptides in practice

Several neuropeptides or their analogs are in clinical or research use:

• Semax — stabilized ACTH(4-7) analog; prescribed in Russia for cognitive enhancement and stroke recovery; acts on BDNF and NGF expression
• Selank — tuftsin analog; anxiolytic and nootropic via GABA-A modulation and enkephalin metabolism
• Oxytocin — intranasal research for social cognition, ASD, PTSD
• DSIP — research peptide for sleep architecture modulation
• VIP — research peptide for CIRS and neuroprotection
• Orexin receptor antagonists — FDA-approved insomnia drugs (the pharmacological inverse of neuropeptide supplementation)

The neuropeptide space is where neuroscience meets peptide therapy — understanding these endogenous signaling molecules provides the mechanistic foundation for why exogenous peptide administration can modulate brain function.